UPDATED: Quanterix raises $46M in Series D round

Molecule testing and diagnostics firm Quanterix Corporation has secured $46 million in Series D funding from both new and existing investors, adding to the $54 million it's raised in previous rounds. The Lexington, MA-based company has recently said it would consider an IPO and there are crossover investors named in the latest round, but it did not discuss any immediate plans to go public in its latest release. A spokesperson for the firm told FierceBiotech: "While the company has not defined a specific timetable for an IPO, it is under consideration based on the company's rapid growth. More specifics will be provided later in the year as plans are further refined." The new money will go towards the launch of desktop instruments in 2017 as well as the development of 60 new assays by the end of the year, while also looking to further its global reach. It currently focuses on oncology, neurology, inflammation, immunology, cardiac and infectious diseases. Report

Suggested Articles

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.

Grid Therapeutics is planning to start trials of its lead cancer immunotherapy GT103 next year after raising $5 million in second-round financing.

The IPO comes as the Flagship startup prepares to test its lead inflammatory disease and anticancer microbial strains in humans.